A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisFrederik Nevens, Д. А. Шапиро, Simon Hohenester et al.|New England Journal of Medicine|2016Cited by 1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #Keith D. Lindor, Felicity Enders, Kris V. Kowdley et al.|Hepatology|2009Cited by 721
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic AcidGideon M. Hirschfield, Д. А. Шапиро, Andrew L. Mason et al.|Gastroenterology|2014Cited by 563
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assayMarlyn J. Mayo, William Rosenberg, Julie Parkes et al.|Hepatology|2008Cited by 199